Beken Bio wins $1.25M federal grant for ovarian cancer blood test
What's the deal? Beken BioDealroom has a profile for this one. Try Dealroom →, a New Orleans biotech startup, has received a $1.25 million federal grant to advance its ovarian cancer blood test. The award funds a multicenter clinical study across Louisiana and moves the company closer to commercialization.
Why now? The Small Business Innovation Research Phase II grant, from the National Science FoundationDealroom has a profile for this one. Try Dealroom →, follows an earlier Phase I grant that supported development of the technology.
What's the endgame? BekenDealroom has a profile for this one. Try Dealroom → Bio is developing a liquid biopsy that uses a blood sample to detect cancer. The Phase II funding will support clinical validation through a prospective study of women undergoing evaluation for pelvic masses at hospitals in New Orleans, Baton Rouge, and Shreveport.
The grant will also fund health economics and reimbursement planning with providers and insurers, plus early development of a second program focused on lung cancer detection.
The company, based at the New Orleans BioInnovation CenterDealroom has a profile for this one. Try Dealroom →, recently expanded its laboratory operations there.
The signal: Federal grants remain a key funding path for early-stage diagnostics startups looking to validate their technology before commercialization.
Read more: New Orleans CityBusiness
Image credit: Beken
